Active CD276 protein-coupled magnetic Beads

• Cat.No.: CD276-0987M

Specification

• Species: Human
• Appearance: Powder mixture
• Particle size: 2 μm
• Source: HEK293
• Protein length: Gly 27 - Thr 461
• Bio-activity: Immobilized 22.7 μg B7-H3(4Ig) to 1mg Beads can bind the Anti B7H3 Ab with an EC50 of 1.039 μg/mL.
• Coupled amount of protein: ≈1988 pmol (100 μg) Human B7-H3(4Ig)/mg beads
• Capacity: >596 pmol (30μg) Anti-B7-H3 Ab/mg beads
• Formulation: PBS, pH7.4, with 10% Trehalose
• Reconstitution: 2 mL sterile deionized water (1 mg beads/mL)
• Background: The Human B7-H3-coupled Magnetic Beads is produced by coupling biotinylated human B7-H3 protein to streptavidin-conjugated magnetic beads. The pre-coupled beads are ready to use for capturing anti-B7-H3 antibody from your sample with high specificity.
• Application: This product is intended for immunocapture, biopanning and flow cytometry. This product is produced non-sterile.
• Storage: Upon receipt, please store the Beads at -20°C for 1 year in lyophilized state.

Reviews

03/15/2022

It has consistently demonstrated high sensitivity and accuracy in detecting and quantifying target molecules, allowing for precise and reliable measurement of analytes in my experimental samples.

08/06/2021

Its versatility and reliability make it an excellent choice for research applications, and I highly recommend it to fellow scientists.

06/03/2021

The sensitivity and specificity of the CD276 Protein have consistently delivered robust and consistent results, enhancing the efficiency and accuracy of my experimental workflows.

Q&As

In which other diseases, besides cancer, is CD276 implicated?

CD276 has been associated with autoimmune diseases and certain inflammatory conditions. Exploring its role in these diseases may open avenues for therapeutic interventions.

Are there diagnostic applications for CD276 in cancer detection?

Research suggests that CD276 expression levels may serve as a diagnostic biomarker for certain cancers. Detection methods, such as immunohistochemistry, are being explored to assess CD276 levels in tumor tissues.

How does CD276 influence the tumor microenvironment?

CD276 can modulate the tumor microenvironment by suppressing immune responses, promoting angiogenesis, and supporting tumor cell survival. Understanding these interactions is crucial for developing targeted therapies.

Are there any ongoing clinical trials focusing on CD276 in cancer patients?

Yes, several clinical trials are underway to evaluate the safety and efficacy of CD276-targeted therapies in different cancer types. These trials aim to assess the impact on patient outcomes and potential side effects.

How does CD276-targeted therapy differ from traditional cancer treatments?

CD276-targeted therapy focuses on modulating the immune response against cancer cells, whereas traditional treatments like chemotherapy and radiation target rapidly dividing cells, including both healthy and cancerous cells.